MBRX News and Press, Moleculin Biotech Inc. From 12/07/22

Moleculin Biotech ( NASDAQ: MBRX ) on Wednesday said it had been granted a fast track designation from the U.S. FDA for its WP1122 treatment for glioblastoma multiforme (GBM), the most aggressive type of brain cancer. The FDA's Fast Track approval is a process designed to facilita...

Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire HOUSTON , Dec. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical com...

Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Walter Klemp – Chairman and Chief Executive Officer Jonathan Foster – Executive Vice President and Chief Financial Officer Conference...

Moleculin Biotech press release ( NASDAQ: MBRX ): Q3 GAAP EPS of -$0.30. The Company ended the quarter with $50.4 million of cash. For further details see: Moleculin Biotech GAAP EPS of -$0.30

Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update PR Newswire – Continued execution across clinical and preclinical development programs – Three Phase 1b /2 clinical studies with enrollment or dosing now under...

Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast PR Newswire HOUSTON , Nov. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Com...

Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK PR Newswire Company enters what it expects to be the final MAD cohort in the first-in-human Phase 1a designed to establish a maximum tolerated dose (...

Moleculin Biotech ( NASDAQ: MBRX ) is trading ~7% higher premarket after it said WP1096 molecule to treat viruses, including arenaviruses will be evaluated in animal studies by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National...

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral PR Newswire – Preclinical work being conducted is intended to validate in vitro findings in established animal models to determine if furth...

Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event PR Newswire – Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annam...